Andrew Ramelmeier, Ph.D.

Dr. R. Andrew “Andy” Ramelmeier is Senior Vice President and Chief Manufacturing and Quality Officer at Sangamo Therapeutics, a leading gene therapy/editing company. He is an accomplished executive and technical leader with over 25 years experience and a strong foundation in development and manufacturing of biopharmaceuticals, including monoclonal antibodies, vaccines, gene and cell therapy products, and therapeutic proteins. Contributed to the licensure of several commercial products (Andexxa, Vimizim, Stelara, Simponi, VAQTA) and process improvements to several other commercial products. Oversaw the design, construction and operation of 6 biologics production facilities, totaling over $400MM in investment. He held leadership roles at Portola Pharmaceuticals, BioMarin Pharmaceuticals, and J&J. He began his industrial career at Merck and Co after post-doctoral work in Germany. He received his Ph.D. in Chemical Engineering at University of California, Berkeley, and a B.S. in Chemical Engineering from Johns Hopkins.